| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BIRB 0796 | GDSC1000 | pan-cancer | AAC | 0.036 | 0.4 |
| mRNA | PD-0332991 | CCLE | pan-cancer | AAC | 0.044 | 0.4 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | -0.033 | 0.4 |
| mRNA | Topotecan | FIMM | pan-cancer | AAC | -0.1 | 0.4 |
| mRNA | EX-527 | GDSC1000 | pan-cancer | AAC | -0.035 | 0.4 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.035 | 0.4 |
| mRNA | AZD6244 | FIMM | pan-cancer | AAC | -0.17 | 0.4 |
| mRNA | JW-7-24-1 | GDSC1000 | pan-cancer | AAC | 0.029 | 0.4 |
| mRNA | navitoclax:pluripotin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.035 | 0.4 |
| mRNA | T0901317 | GDSC1000 | pan-cancer | AAC | -0.033 | 0.4 |